<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04724239</url>
  </required_header>
  <id_info>
    <org_study_id>CIBI387Y101</org_study_id>
    <nct_id>NCT04724239</nct_id>
  </id_info>
  <brief_title>A Study of Sintilimab and Chidamide in Combination With or Without IBI305 in Standard Treatment Failure of Advanced or Metastatic pMMR/MSS Colorectal Carcinoma</brief_title>
  <official_title>A Multicenter, Open, Randomized Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Sintilimab and Chidamide in Combination With or Without IBI305 in Patients With Standard Treatment Failure of Advanced or Metastatic pMMR/MSS Colorectal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of sintilimab and chidamide&#xD;
      in combination with or without IBI305 in patients with standard treatment failure of advanced&#xD;
      or metastatic pMMR/MSS colorectal adenocarcinoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects will be randomized in approximately a 1:1 ratio to receive sintilimab and chidamide with or without IBI305.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The progression-free survival (PFS) rates at 18 weeks</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS);</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS);</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DoR)</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Advanced Microsatellite Stable Colorectal Cancer</condition>
  <condition>Metastatic Microsatellite-stable Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>sintilimab + chidamide + IBI305</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>sintilimab + chidamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sintilimab</intervention_name>
    <description>200mg IV on Day 1 Q3W</description>
    <arm_group_label>sintilimab + chidamide</arm_group_label>
    <arm_group_label>sintilimab + chidamide + IBI305</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chidamide</intervention_name>
    <description>30mg PO BIW each 3-week cycle</description>
    <arm_group_label>sintilimab + chidamide</arm_group_label>
    <arm_group_label>sintilimab + chidamide + IBI305</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI305</intervention_name>
    <description>7.5mg/kg IV on Day 1 Q3W</description>
    <arm_group_label>sintilimab + chidamide + IBI305</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed diagnosis of unresectable locally advanced, recurrent or&#xD;
             metastatic colorectal adenocarcinoma.&#xD;
&#xD;
          2. Tumor tissues were identified as mismatch repair-proficient (pMMR) by&#xD;
             immunohistochemistry (IHC) method or microsatellite stability (MSS) by polymerase&#xD;
             chain reaction (PCR).&#xD;
&#xD;
          3. Subjects must have failed at least two lines of prior treatment.&#xD;
&#xD;
          4. Subjects must have one measurable lesion according to RECIST v1.1 at least.&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.&#xD;
&#xD;
          6. 18-75 years old.&#xD;
&#xD;
          7. Life expectancy of at least 12 weeks.&#xD;
&#xD;
          8. Adequate bone marrow, liver, renal and coagulation function as assessed by the&#xD;
             laboratory required by protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previously received anti-programmed death-1 (PD-1) or its ligand (PD-L1) antibody or&#xD;
             histone deacetylase (HDAC) inhibitor.&#xD;
&#xD;
          2. Received last dose of anti-tumor therapy (chemotherapy, targeted therapy, tumor&#xD;
             immunotherapy or arterial embolization) within 3 weeks of the first dose of study&#xD;
             medication.&#xD;
&#xD;
          3. Received radiotherapy with 4 weeks of the first dose of study medication.&#xD;
&#xD;
          4. Underwent major operation within 4 weeks of the first dose of study medication or open&#xD;
             wound, ulcer or fracture.&#xD;
&#xD;
          5. Known symptomatic central nervous system (CNS) metastasis and/or carcinomatous&#xD;
             meningitis. Subjects received prior treatment and have stable disease more than 4&#xD;
             weeks from first dose of study medication are permitted to enroll.&#xD;
&#xD;
          6. Active, known or suspected autoimmune disease or has a history of the disease within&#xD;
             the last 2 years.&#xD;
&#xD;
          7. Interstitial lung disease requiring corticosteroids.&#xD;
&#xD;
          8. Active or poorly controlled serious infections.&#xD;
&#xD;
          9. Significant malnutrition.&#xD;
&#xD;
         10. Symptomatic congestive heart failure (NYHA Class II-IV) or symptomatic or poorly&#xD;
             controlled arrhythmia.&#xD;
&#xD;
         11. Uncontrolled hypertension (systolic blood pressure ≥ 150 mmHg or diastolic blood&#xD;
             pressure ≥ 100 mmHg) despite standard treatment.&#xD;
&#xD;
         12. Within 6 months prior to the enrollment, history of gastrointestinal perforation&#xD;
             and/or fistula, gastrointestinal ulcer, bowel obstruction, extensive bowel resection,&#xD;
             Crohn's disease, or ulcerative colitis, intra-abdominal abscesses, or long-term&#xD;
             chronic diarrhea.&#xD;
&#xD;
         13. History or evidence of inherited bleeding diathesis or coagulopathy or thrombus&#xD;
&#xD;
         14. Any life-threatening bleeding within 3 months prior to the enrollment.&#xD;
&#xD;
         15. High risk of bleeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Feng Wang, MD, PhD</last_name>
    <phone>86-20-87343795</phone>
    <email>wangfeng@sysucc.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ruihua Xu, MD, PhD</last_name>
    <phone>86-20-87343333</phone>
    <email>xuruihua@sysucc.org.cn</email>
  </overall_contact_backup>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 25, 2021</study_first_submitted>
  <study_first_submitted_qc>January 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 26, 2021</study_first_posted>
  <last_update_submitted>February 3, 2021</last_update_submitted>
  <last_update_submitted_qc>February 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Ruihua Xu</investigator_full_name>
    <investigator_title>The president of Sun Yat-sen University Cancer Center</investigator_title>
  </responsible_party>
  <keyword>Colorectal Carcinoma, pMMR, Microsatellite-stable</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

